Clinical Gastroenterology Vol.24 No.5(11)

Theme GERD -- Recent Clinical Advances
Title Treatment of Gastroesophageal Reflux Disease -- Recent Studies
Publish Date 2009/05
Author Shigeaki Yasaka Department of Gastroenterology, Oita University Faculty of Medicine
Author Kazunari Murakami Department of Gastroenterology, Oita University Faculty of Medicine
Author Takashi Abe Department of Gastroenterology, Oita University Faculty of Medicine
Author Juro Anan Department of Gastroenterology, Oita University Faculty of Medicine
Author Kazuhiro Mizukami Department of Gastroenterology, Oita University Faculty of Medicine
Author Jin Tanahashi Department of Gastroenterology, Oita University Faculty of Medicine
Author Tadayoshi Okimoto Department of Gastroenterology, Oita University Faculty of Medicine
Author Masaaki Kodama Department of Gastroenterology, Oita University Faculty of Medicine
Author Toshio Fujioka Department of Gastroenterology, Oita University Faculty of Medicine
[ Summary ] For the treatment of GERD patients, antisecretory drugs are primarily used. Proton pump inhibitors (PPIs) are more effective than H2-receptor antagonists (H2RAs) and are drugs of first choice. To properly employ these drugs we should know their characteristics, in order to make appropriate therapeutic decisions.
The pharmacological activity of PPIs in the stomach, activity of metabolic enzyme (CYP2C19), and nocturnal gastric acid breakthroughs indicate the possibility of PPI-resistance. In such cases, we must consider changing the time of administration, dosage and type of drugs in order to continue long-term therapy.
With the recent introduction of examinations to observe simultaneous intraesophageal impedance and pH measurement, non-acid reflux has been recognized. It has been reported that mosapride may improve esophageal function and reduce esophagitis. The GABA(B) agonist baclofen controls transient lower esophageal sphincter relaxations and decreases acidic and non-acidic post-prandial gastro-oesophageal reflux.
back